BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex

Journal of Neurochemistry

Volumn 69, Issue 1, 1997, Pages 182-190

  Volonté, Marina ^a   Monferini, Eugenia ^a   Cerutti, Monica ^a   Fodritto, Fabio ^a   Borsini, Franco ^a  

^a Boehringer Ingelheim Italia SpA   (Italy)

Author keywords

Antipsychotics; BIMG 80; Dopamine; Nucleus accumbens; Prefrontal cortex; striatum

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY 3 [N [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 1,2,5,6 TETRAHYDROPYRIDIN 3 YLMETHYL] 1H INDOLE; ALPRENOLOL; AMPEROZIDE; ATROPINE; BIMG 80; CLONIDINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; HISTAMINE; KETANSERIN; LYSERGIDE; MEPYRAMINE; MESULERGINE; METHYSERGIDE; MIANSERIN; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PIRENZEPINE; PRAMIPEXOLE; PRAZOSIN; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN; TALIPEXOLE; TIOTIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0030973374     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69010182.x     Document Type: Article

References (52)

1. Andersson J. L., Marcus M., Nomikos G. G., and Svensson T. H. (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedebergs Arch. Pharmacol. 349, 236-243.
2. Andreasen N. C., Arndt S., Swayze V. II, Cizadlo T., Flaum M., O'Leary D., Ehrhardt J. C., and Yuh W. T. C. (1994) Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266, 294-297.
3. Arborelius L., Nomikos G. G., Hacksell U., and Svensson T. H. (1993a) (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148, 465-466.
4. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch. Pharmacol. 347, 353-362.
5. Artigas F., Pérez V., and Alvarez E. (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51, 248-251.
6. 2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res. 506, 346-348.
7. Blier P. and Bergeron R. (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15, 217-222.
8. 2 receptor function: hypothesis for a faster antidepressant action. Pharmacol. Res. 30, 1-11.
9. 1A receptor full agonist in rat cerebral cortex. Naunyn Schmiedebergs Arch. Pharmacol. 352, 276-282.
10. Brambilla A., Cesana R., Gil M., and Borsini F. (1995) Pharmacological profile of BIMG 80, a novel potential atypical antipsychotic [Abstr. P-4-10]. Eur. Neuropsychopharmacol. 5, 329.
11. Bylund D. B. and Snyder S. H. (1976) β-Adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 12, 568-580.
12. Bymaster F. P., Calligaro D. O., Falcone J. F., Marsh R. D., Moore N. A., Tye N. C., Seeman P., and Wong D. T. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
13. 3H]-mepyramine binding of brain membranes. J. Neurochem. 32, 1653-1663.
14. Chouinard G., Jones B., Remington G., Bloom D., Addington D., Macewan G. W., Labelle A., Beauclair L., and Arnott W. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia. J. Clin. Psychopharmacol. 13, 25-40.
15. Claas F. (1989) Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacology (Berlin) 99 (Suppl.), S113-S117.
16. 2/1C antagonist, and negative symptoms in schizophrenia. Br. J. Psychiatry 163, 451-455.
17. 4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285. Naunyn Schmiedebergs Arch. Pharmacol. 345, 264-269.
18. 2 receptors in guinea pig cerebral cortex. Nature 304, 65-67.
19. Gerlach J. and Peacock L. (1995) New antipsychotics: the present status. Int. Clin. Psychopharmacol. 10, 39-48.
20. Greenberg D. A., U'Prichard D. C., and Snyder S. H. (1976) Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states. Life Sci. 19, 69-76.
21. 3H]-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 55, 323-326.
22. 3 receptor: implication for treatment of schizophrenia. Presentation at the First International Symposium on Schizophrenia, IBC's Symposium, May 8-9, Philadelphia.
23. Haase H. J. (1978) The purely neuroleptic effects and its relation to the "neuroleptic threshold." Acta Psychiatr. Belg. 78, 19-36.
24. Hammer R., Giraldo E., Schiavi G. B., Monferini E., and Ladinsky H. (1986) Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 38, 1653-1662.
25. Hertel P., Nomikos G. G., Iurlo M., and Svensson T. H. (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berlin) 124, 74-86.
26. Hicks P. B. (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47, 1609-1615.
27. 1 receptors in guinea pig brain. J. Neurochem. 31, 997-1004.
28. Kane J. M., Honigfeld G., Singer J., and Meltzer H. Y. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with clorpromazine. Arch. Gen. Psychiatry 45, 789-796.
29. Karreman M. and Moghaddam B. (1996) The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 66, 589-598.
30. König J. F. R. and Klippel R. A. (1974) The Rat Brain, a Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. Krieger, New York.
31. 2 receptor occupancy: implications for antipsychotic action. Eur. J. Pharmacol. 216, 67-71.
32. 4 receptors. Eur. J. Pharmacol. 290, 29-36.
33. Migler B. M., Warawa E. J., and Malick J. B. (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology (Berlin) 112, 299-307.
34. Moghaddam B. and Bunney B. S. (1990) Acute effect of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 1755-1760.
35. Monsma F. J., Shen Y., Ward R. P., Hamblin M. W., and Sibley D. R. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43, 320-327.
36. Moore N. A., Calligaro D. O., Wong D. T., Bymaster F., and Tye N. C. (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Investigatory Drugs 2, 281-293.
37. Nomikos G. G., Iurlo M., Andersson J. L., Kimura K., and Svensson T. H. (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berlin) 115, 147-156.
38. Paul S. M. (1995) Olanzepine: efficacy and safety of a new atypical antipsychotic. Presentation at the First International Symposium on Schizophrenia, IBC's Symposium, May 8-9, Philadelphia.
39. 2-adrenergic receptors in rat brain. Proc. Natl. Acad. Sci. USA 81, 1585-1589.
40. Roth B. L., Craigo S. C., Choudhary M. S., Uluer A., Monsma F. J. Jr., Shen Y., Meltzer H. Y., and Sibley D. R. (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268, 1403-1410.
41. Sailer C. F. and Salama A. I. (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berlin) 112, 285-292.
42. Santiago M., Machado A., and Cano J. (1993) Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur. J. Pharmacol. 239, 83-91.
43. 4 sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 33, 543-549.
44. Sommermeyer H. (1994) Modulation of dopaminergic neurotransmission in the rat by haloperidol, 8-OH-DPAT, or simultaneous administration of both, in 6th International Conference on In Vivo Methods, pp. 239-240.
45. 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15, 11S-18S.
46. Swanson L. W. (1982) The projections of the ventral tegmental area and the adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. 9, 321-353.
47. Tanda G., Carboni E., Frau R., and Di Chiara G. (1994) Increase in extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential. Psychopharmacology (Berlin) 115, 285-288.
48. Tassin J. P., Trovero F., Blanc G., Herve D., and Glowinski J. (1994) Functional implications of noradrenergic-dopaminergic interactions in the prefrontal cortex. Behav. Pharmacol. 5, 35.
49. 1-adrenergic receptor subtype to expression of the "ventral tegmental area syndrome." Neuroscience 47, 69-76.
50. 3 receptor antagonist Itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. J. Pharmacol. Exp. Ther. 275, 358-367.
51. Volonté M., Cerutti M., Giraldo E., Gil M., Fodritto F., and Borsini F. (1995b) Effect of BIMG 80, a novel potential atypical antipsychotic on dopamine levels measured by microdialysis (Abstr. P-4-9). Eur. Neuropsychopharmacol. 5, 329.
52. 1 dopamine receptor. Nature 347, 76-80.